BR112021023765A2 - Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto - Google Patents

Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto

Info

Publication number
BR112021023765A2
BR112021023765A2 BR112021023765A BR112021023765A BR112021023765A2 BR 112021023765 A2 BR112021023765 A2 BR 112021023765A2 BR 112021023765 A BR112021023765 A BR 112021023765A BR 112021023765 A BR112021023765 A BR 112021023765A BR 112021023765 A2 BR112021023765 A2 BR 112021023765A2
Authority
BR
Brazil
Prior art keywords
compound
formula
pharmaceutically acceptable
application
aurora kinase
Prior art date
Application number
BR112021023765A
Other languages
English (en)
Inventor
Houxing Fan
Yuli Xie
Original Assignee
Wigen Biomedicine Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Tech Shanghai Co Ltd filed Critical Wigen Biomedicine Tech Shanghai Co Ltd
Publication of BR112021023765A2 publication Critical patent/BR112021023765A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto. a invenção refere-se a um tipo de composto de piridina inovador e um método de preparação e aplicação do mesmo. especificamente, a invenção se refere a um composto de fórmula (1) e um método de preparação do mesmo, e uma aplicação do composto de fórmula (1) e sais farmaceuticamente aceitáveis dos mesmos como inibidores de aurora quinase na preparação de fármacos antitumorais.
BR112021023765A 2019-07-16 2020-06-29 Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto BR112021023765A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910643061.2A CN112239465A (zh) 2019-07-16 2019-07-16 极光激酶抑制剂及其用途
PCT/CN2020/098775 WO2021008338A1 (zh) 2019-07-16 2020-06-29 极光激酶抑制剂及其用途

Publications (1)

Publication Number Publication Date
BR112021023765A2 true BR112021023765A2 (pt) 2022-01-25

Family

ID=74166907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023765A BR112021023765A2 (pt) 2019-07-16 2020-06-29 Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto

Country Status (10)

Country Link
US (1) US20210198261A1 (pt)
EP (1) EP4001276A4 (pt)
JP (1) JP2022541467A (pt)
KR (1) KR20220035031A (pt)
CN (2) CN112239465A (pt)
AU (1) AU2020314910A1 (pt)
BR (1) BR112021023765A2 (pt)
CA (1) CA3142069A1 (pt)
MX (1) MX2021013981A (pt)
WO (1) WO2021008338A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
AR126581A1 (es) * 2021-07-28 2023-10-25 Jacobio Pharmaceuticals Co Ltd Formas polimórficas de inhibidores selectivos de aurora a y usos de las mismas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009216062B2 (en) * 2008-02-22 2013-02-07 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9012475B2 (en) * 2013-08-27 2015-04-21 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
US11028069B2 (en) * 2016-12-22 2021-06-08 Taiho Pharmaceutical Co., Ltd. Salt of substituted piperidine compound
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物

Also Published As

Publication number Publication date
MX2021013981A (es) 2022-01-18
CN112239465A (zh) 2021-01-19
US20210198261A1 (en) 2021-07-01
AU2020314910A1 (en) 2022-01-27
KR20220035031A (ko) 2022-03-21
CN114072400A (zh) 2022-02-18
EP4001276A1 (en) 2022-05-25
CN114072400B (zh) 2023-04-07
JP2022541467A (ja) 2022-09-26
WO2021008338A1 (zh) 2021-01-21
CA3142069A1 (en) 2021-01-21
EP4001276A4 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
BR112016016844A2 (pt) Compostos heterocíclicos
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
BR112015022785A2 (pt) composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
PH12017502418A1 (en) 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
BR112016006651B8 (pt) compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112018073524A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
MY196788A (en) Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
BR112021023765A2 (pt) Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201990343A1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2